A study of GMA 204 for the treatment of Non-small cell lung cancer.

Trial Profile

A study of GMA 204 for the treatment of Non-small cell lung cancer.

Planning
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs GMA 204 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Jan 2017 New trial record
    • 29 Oct 2015 According to a Gmax Biopharm media release, GMA204 clinical research application has been submiteed to Zhejiang Provincial Food and Drug Administration (CFDA)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top